Collaboration to drive innovation across healthcare ecosystem CAMBRIDGE, MA, 21 SEPTEMBER 2018–FasterCures, a center of the Milken Institute devoted to saving lives by speeding up and improving the medical research … Read More
Improving Management of Gene and Cell Therapies: The Orphan Reinsurer and Benefit Manager (ORBM)
D. Han; D.S. Mytelka; G.L. Warren; M. Ciarametaro; M. Trusheim. PharmaExec.com, 2018 After decades of anticipation, 2017 saw the approval of the first of a new generation of durable and … Read More
Improving Management of Gene and Cell Therapies
Pharmaceutical Executive, September 10, 2018Michael Ciarametaro, Mark Trusheim, Daniel S. Mytelka, Gregory L. Warren, and Donald Han After decades of anticipation, 2017 saw the approval of the first of a … Read More
FoCUS Research Team interviewed for article on Innovating Payment Models
The leads of the FoCUS Research Teams, Strategic Director Mark Trusheim, Research Advisor Casey Quinn, Director of Simulation & Policy Research Daniel Mytelka, and Director of Drug Development Pipeline Research … Read More
Designing financial solutions to ensure affordable access to cures
The reimbursement of emerging durable/potentially curative cell and gene therapies is likely to be a challenge for the US healthcare market. Considering the pricing of cell- and gene-based therapies approved … Read More
LEAPS Announces Disease Area for Pilot Project
Participants in the first LEAPS Design Lab in July 2018 were tasked with considering disease areas offering the prospect of significant healthcare impact and identifying early practical and technical challenges … Read More
LEAPS project at MIT aims to pilot “learning ecosystem” for patient-centered biomedical innovation
New initiative aims to improve decision-making across biopharmaceutical development and delivery lifecycle CAMBRIDGE, 23 July 2018—The NEWDIGS Initiative at the Massachusetts Institute of Technology (MIT) hosted a Design Lab … Read More
FoCUS responds to HHS “Blueprint” Request for Information
Federal initiative seeks to make access to innovative therapies wider and more financially sustainable On May 16, 2018 the US Department of Health and Human Services (HHS) published a … Read More
Stop-Loss Insurance or Reinsurance for Multiyear Contracts
In previous Research Briefs, we have discussed challenges faced by payers when contemplating using multiyear performance-based contracts. In this brief, we extend the discussion to include additional difficulties that may … Read More
Impact of Patient Mobility on Annuity/Performance-Based Contracting
Spreading payments over time for durable or curative therapies can provide a better alignment between benefits and costs, but creates challenges when patients switch insurance coverage during the contract term. … Read More